Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Not yet recruiting · NCT07776171 · Registry updated 2026-08-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, carcinoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Not yet recruiting | Phase 2 | 2026-08-20 | NCT07776171 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sun Yat-sen University | 606 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Sun Yat-sen University Cancer Center | Guangzhou | China | 315 |